FRA:UDD (Australia)  
Prescient Therapeutics Ltd logo

Prescient Therapeutics Ltd

€ 0.11 (-5.17%) Aug 18
P/E:
At Loss
P/B:
4.90
Market Cap:
€ 82.40M ($ 89.75M)
Enterprise V:
€ 74.37M ($ 81.00M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap €:
82.40M
Market Cap $:
89.75M
PE Ratio:
At Loss
Avg Vol (2-Month):
-
Enterprise Value €:
74.37M
Enterprise Value $:
81.00M
PB Ratio:
4.90

Business Description

Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.95
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Beneish M-Score -4.11
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % 71.03
12-1 Month Momentum % 281.54

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.61
Quick Ratio 17.61
Cash Ratio 15.18

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.4